stockrowRoivant Sciences Ltd.
ROIV Healthcare Biotechnology
Roivant Sciences Ltd.’s revenue for fiscal 2026 (year ended March 2026) was $8.3 million, down 71.6% from fiscal 2025.
- Revenue
- −33.6%
- EPS
- +21.2%
- Free cash flow
- −30.0%
Quarter to June 2026, against a year earlier
Follow ROIV
Alert me
Roivant Sciences Ltd. (ROIV) Operating cash flow
Roivant Sciences Ltd.'s operating cash flow for fiscal 2026 was −$750.3M, compared with −$839.5M in fiscal 2025. Over the twelve months to 30 June 2026 it was −$816.5M. Over the past ten years it has ranged from −$843.4M (fiscal 2023) to −$249.0K (fiscal 2020); the current reading is higher than 57% of that period. Roivant Sciences Ltd. ranks 600th of 603 Biotechnology companies by operating cash flow.
Operating cash flow, annual
Embed this chart
Annual newest first
| Period | Operating cash flow | Change |
|---|---|---|
| FY2026 | −$750.3M | — |
| FY2025 | −$839.5M | — |
| FY2024 | −$765.3M | — |
| FY2023 | −$843.4M | — |
| FY2022 | −$677.7M | — |
| FY2021 | −$552.1M | — |
| FY2020 | −$249.0K | — |
Quarterly newest first
| Period | Operating cash flow | Change |
|---|---|---|
| Jun 2026 | −$270.5M | — |
| Mar 2026 | −$163.8M | — |
| Dec 2025 | −$196.5M | — |
| Sep 2025 | −$185.7M | — |
| 21 more quarters | Free account |
Against its own ten years
Operating cash flow against peers
| Company | Operating cash flow |
|---|---|
| RPRX Royalty Pharma PLC compare | $3.0B |
| ONC BeOne Medicines Ltd. - Sponsored ADR compare | $1.6B |
| ALNY Alnylam Pharmaceuticals, Inc. compare | $955.9M |
| GMAB Genmab A/S Sponsored ADR compare | $891.0M |
| INCY Incyte Corporation compare | $745.0M |
| BNTX BioNTech SE Sponsored ADR compare | −$277.2M |
| INSM Insmed, Inc. compare | −$595.6M |
| ROIV Roivant Sciences Ltd. | −$816.5M |
| RVMD Revolution Medicines, Inc. compare | −$1.4B |
What Operating cash flow is
Operating Cash Flow shows how much cash a company’s day-to-day business actually brings in, after paying suppliers, staff and taxes.
Reported line item
More on ROIV
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- The full statement